

1st Annual Canadian Biomarker and Surrogate Endpoints Symposium
January 5, 2009
Ottawa, Ontario

Agenda:

8:00 – 8:15 AM **Opening Remarks**
Peter Libby, MD, Brigham and Women's Hospital, Harvard Medical School
Jean-Claude Tardif, MD, Montreal Heart Institute, University of Montreal

Session 1 – Cardiovascular Focus - Atherosclerosis Imaging Technologies

8:15 – 8:45 AM **Quantitative Coronary Arteriography to Assess the Effect of Pharmacologic Agents on the Progression/Regression of Coronary Atherosclerosis**
David Waters, MD, University of California, San Francisco

8:45 – 9:15 AM **Intravascular Ultrasound**
Jean-Claude Tardif, MD, Montreal Heart Institute, University of Montreal

9:15 – 9:45 AM **Carotid Intima Media Thickness: Use in Cardiovascular Risk Assessment and in Clinical Trials**
Eva Lonn, MD, McMaster University

9:45 – 10:15 AM **Carotid Ultrasound Phenotypes: Assessing Atherosclerosis Burden and Response to Therapy**
J. David Spence, MD, Robarts Research Institute

10:15 – 10:30 AM **BREAK**

10:30 – 11:00 AM **Magnetic Resonance Imaging**
Alan Moody, MD Sunnybrook Health Sciences Centre

11:00 – 11:30 PM **Computed Tomography and Positron Emission Tomography**
Zahi Fayad, MD, Mount Sinai School of Medicine

11:30 – 12:00 PM **PET as a Tool For Molecular Imaging**
Robert Beanlands, MD, University of Ottawa Heart

12:00 – 12:30 PM **LUNCH**

12:30 – 1:30 PM **Panel Discussion**
Peter Libby, MD, Brigham and Women's Hospital, Harvard Medical School
Jean-Claude Tardif, MD, Montreal Heart Institute, University of Montreal
David Waters, MD, University of California, San Francisco
J. David Spence, Robarts Research Institute
Alan Moody, MD Sunnybrook Health Sciences Centre
Zahi Fayad, MD, Mount Sinai School of Medicine
Robert Beanlands, MD, University of Ottawa Heart
Eva Lonn, MD, McMaster University

1:30 – 2:00 PM **New Development in Atherosclerosis Imaging Technologies**
Philippe L'Allier, MD, Montreal Heart Institute

2:00 – 2:30 PM **Cardiovascular Imaging Initiatives**
Peter Liu, MD, Canadian Institutes of Health Research

2:30 – 3:00 PM **Rewards and Risks of using Surrogate Endpoints in the Approval of Drugs**
Agnes Klein, MD, Health Canada

1st Annual Canadian Biomarker and Surrogate Endpoints Symposium
January 5, 2009
Ottawa, Ontario

3:00 – 3:30 PM

Panel Discussion

Peter Libby, MD, Brigham and Women's Hospital, Harvard Medical School
Jean-Claude Tardif, MD, Montreal Heart Institute, University of Montreal
Philippe L'Allier, MD, Montreal Heart Institute
Peter Liu, MD, Canadian Institutes of Health Research
Agnes Klein, MD, Health Canada

3:30 – 4:00 PM

BREAK

Session 2 - New Frontiers in Imaging Biomarkers - Molecular Imaging Technologies

4:00 – 4:30 PM

Molecular Imaging Innovations in Cardiovascular Disease

Peter Libby, MD, Brigham and Women's Hospital, Harvard Medical School

4:30 – 5:00 PM

An Approach to the Commercial Development of Molecular Imaging Agents

Allison Mueller, Director, GE Healthcare

5:00 – 6:00 PM

Panel Discussions: Academia, Industry and Regulatory Agency: Working Together For the Future

Faculty Members

6:00 – 7:30 PM

DINNER